Medicare AdvantagePrior AuthMedium impact
Alternate nilotinib products (Danziten, Cavhanza, nilotinib tartrate-Cipla) (Revised)
Humana·Oncology, Hematology·Medicare Advantage
Effective date
Feb 26, 2025
We identified it
Jul 22, 2026
Summary
This revised Humana Medicare Advantage prior authorization policy covers three alternate nilotinib products (Danziten, Cavhanza, and nilotinib tartrate-Cipla) for chronic myeloid leukemia treatment. The policy requires prior authorization and establishes approval criteria: members must have a CML diagnosis, be 18+ years old, and have not experienced disease progression on any prior nilotinib product. A black box warning highlights QT prolongation risks and requires baseline/periodic ECG monitoring.
Action Required
By February 26, 2025: Billing and clinical teams must implement prior authorization requirements for all claims involving Danziten (nilotinib tablets), Cavhanza (nilotinib disintegrating tablets), and nilotinib tartrate-Cipla capsules for Humana Medicare Advantage members. Update billing system and prior auth submission processes to verify: (1) member has confirmed CML diagnosis, (2) member age 18+, and (3) no prior disease progression on nilotinib products. Flag any claims with history of nilotinib disease progression for denial. Ensure providers document baseline ECG, electrolyte levels (potassium/magnesium), and QTc monitoring plan before prior auth approval. Train authorization staff on black box warning contraindications (hypokalemia, hypomagnesemia, long QT syndrome). Failure to obtain prior authorization will result in claim denials for Humana MA plans.